Zahidah Abu Seman1, Ermi Neiza Mohd Sahid1, Dr Azian Naila Md Nor1, Julia Abdullah1, Nurul Aqilah Ali1, Fifi Shawani Abtah1, Siti Noorain Mohd Razali1, Mohd Khairul Nizam Mohd Khalid2, Yuslina Mat Yusoff1*
1. Hematology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, 40170, Selangor, Malaysia
2. Inborn Error of Metabolism and Genetic Unit, Metabolic & Cardiovascular Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Nutrition, Shah Alam, 40170, Selangor, Malaysia
*Corresponding author: Yuslina Mat Yusoff.
ABSTRACT
INTRODUCTION: Acute myeloid leukaemia (AML) is a genetically heterogeneous malignancy characterised by a diverse array of somatic mutations. Advances in next-generation sequencing (NGS), including targeted panels and whole exome sequencing (WES), have significantly enhanced the molecular characterisation of AML.
OBJECTIVE(S): This study aimed to evaluate and compare the mutation detection capabilities of targeted NGS myeloid panels and WES in AML patients.
MATERIALS & METHODS: This study analysed archived samples from 48 AML patients. WES was performed on all 48 samples using the MGI DNBSEQ platform. Targeted NGS using myeloid gene panels was additionally conducted on a subset of 16 patients using the Illumina MiSeq platform. Variant analysis was carried out using QIAGEN Clinical Insight (QCI) Interpret, aligned to the GRCh38 reference genome. Pathogenic and likely pathogenic variants were selected based on in silico prediction and manual review using Integrative Genomics Viewer (IGV).
RESULTS: WES of 48 AML samples identified 42 pathogenic and likely pathogenic variants across 31 distinct genes, including ASXL1, ASXL2, BAP1, BCOR, BCORL1, CEBPA, CHEK2, DNMT3A, ETV6, FLT3, GATA2, IDH1, IDH2, IKZF1, KMT2C, KRAS, SRSF2, MUTYH, NPM1, NRAS, PHF6, PTPN11, RUNX1, SETD2, SF3B1, STAG2, TET2, TP53, U2AF1, WT1 and ZBTB7A. In the 16-patient subset, 35 variants in 17 genes (ASXL1, CEBPA, DNMT3A, ETV6, GATA2, IDH1, IDH2, KRAS, SRSF2, NPM1, NRAS, PHF6, RUNX1, STAG2, TET2, TP53 and WT1) were concordantly detected by both targeted NGS and WES. Notably, WES additionally identified variants in 3 genes (ASXL2, MUTYH and ZBTB7A) not covered by the targeted panel in this subset.
CONCLUSION: This study highlights that targeted NGS is effective in identifying mutations within established AML-associated genes. However, WES offers a more comprehensive genomic overview and potentially uncovers additional clinically relevant variants not captured by targeted panels. These findings underscore the complementary role of both approaches in comprehensive AML genomic characterisation.
KEYWORDS: Acute Myeloid Leukaemia (AML), Next-Generation Sequencing (NGS), Whole Exome Sequencing (WES), Targeted NGS, Variant Detection


